Our current work examined whether SAMe and MTA may target the miR-34a/b-MAT2A/2B axis because of the finding from Rokavec et al. that IL-6-activated STAT3 suppressed miR-34a expression and inhibited CRC migration and invasion [5]. The gene discussed is STAT3; the disease is colorectal carcinoma.